UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 

 

FORM 8-K

 

CURRENT REPORT Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported)   September 27, 2016

 

Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

(State or Other Jurisdiction of Incorporation)

 

001-32715 94-3123681
(Commission File Number) (IRS Employer Identification No.)

 

135 Beaver Street Waltham, MA 02452
(Address of Principal Executive Offices) (Zip Code)

 

(781) 398-0700

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

ITEM 1.01ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

On September 27, 2016, Interleukin Genetics, Inc. (the “Company”) entered into a Third Amendment to Commercial Lease (the “Third Amendment”) with Clematis LLC (“Lessor”) to amend the Commercial Lease (“Lease”), dated February 13, 2004, between the Company and the Lessor, as amended on November 18, 2008 and on February 7, 2014. The Third Amendment extends the term of the lease from April 1, 2017 to March 31, 2019.

 

A copy of the Third Amendment is being filed herewith as Exhibit 10.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

 

 

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS.

 

(d)Exhibits.

 

10.1 Third Amendment to Commercial Lease, dated as of September 27, 2016, by and between the Company and Clematis, LLC.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Interleukin Genetics, Inc.  
  (Registrant)  
     
     
Date: September 30, 2016 /s/ Stephen DiPalma
  Stephen DiPalma  
  Interim Chief Financial Officer  
  (Signature)